Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials

Mario Balducci, Gian Carlo Mattiucci, Cesare Colosimo, Vincenzo Valentini, Alba Fiorentino, Pasquale De Bonis, Silvia Chiesa, Annunziato Mangiola, Giuseppe Roberto D'Agostino, Vincenzo Frascino, Giovanna Mantini, Anna Rita Alitto, Carmelo Anile, A. Fiorentino

Risultato della ricerca: Contributo in rivistaArticolo in rivista

8 Citazioni (Scopus)

Abstract

To investigate the impact of nonstandard concomitant temozolomide (TMZ) administration in two prospective phase II studies for glioblastoma (GBM).
Lingua originaleEnglish
pagine (da-a)926-931
Numero di pagine6
RivistaStrahlentherapie und Onkologie
Volume189
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Alkylating
  • Brain Neoplasms
  • Chemoradiotherapy, Adjuvant
  • Clinical Trials, Phase II as Topic
  • Combined Modality Therapy
  • Dacarbazine
  • Disease-Free Survival
  • Glioblastoma
  • Humans
  • Italy
  • Middle Aged
  • Prevalence
  • Prospective Studies
  • Risk Assessment
  • Survival Rate
  • Treatment Outcome
  • Young Adult

Fingerprint Entra nei temi di ricerca di 'Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials'. Insieme formano una fingerprint unica.

Cita questo